Senior Management Team
Scientific Advisory Board
Dr. Lee Goldstein, MD, PhD, Chair Scientific Advisory Board
Dr. Goldstein is currently a member of the faculty of Boston University, in the Departments of
Psychiatry, Ophthalmology, Neurology, Pathology, and Laboratory Medicine, as well as the College of Engineering in the Department of Biomedical Engineering. He is also a member of the research faculty at the Photonics Center of Boston University.
Prior to joining Boston University, Dr. Goldstein was Assistant Professor of Psychiatry, Harvard Medical School; Director, Molecular Aging & Development Lab and Center for Biomedical Metallomics at Brigham and Women’s Hospital, Boston. Dr. Goldstein is a board-certified psychiatrist who specializes in geriatric psychiatry at the Brigham & Women's and Massachusetts General Hospitals. Dr. Goldstein received his medical and doctoral (Neuroscience) degrees from Yale University and is a Phi Beta Kappa graduate of Columbia University. Dr. Goldstein conducted advanced postdoctoral research in AD and cataract pathophysiology at Harvard. He discovered beta amyloid in the lens of Alzheimer’s subjects and continues world leading research in ocular diagnosis of Alzheimer’s and other neurodegenerative diseases.
Rudolph E. Tanzi, PhD, Scientific Advisory Board Member
Dr. Tanzi is Professor of Neurology and Neuroscience at Harvard Medical School and Director of the Genetics and Aging Unit at the Massachusetts General Hospital. Dr. Tanzi is one of the world’s leading authorities on Alzheimer’s disease and a leading research force in understanding the genetic, cellular, and molecular pathophysiology of neurodegenerative disease. Dr. Tanzi has contributed groundbreaking work on genotype analysis of complex diseases, Huntington’s disease, Alzheimer’s disease, and general aspects of aging. Dr. Tanzi isolated the first familial Alzheimer’s disease gene. Dr. Tanzi serves on a number of editorial boards and has received numerous accolades for his research. Dr. Tanzi is the author of the popular book Decoding Darkness: The Search for Genetic Causes of AD.
William E. Klunk, MD, PhD, Scientific Advisory Board Member
Dr. Klunk is an Associate Professor of Psychiatry at the University of Pittsburgh School of Medicine in Pittsburgh, Pennsylvania. In addition, he is Director of the Laboratory of Molecular Neuropharmacology at Western Psychiatric Institute and Clinic and Associate Director of the Clinical Core and Director of Psychiatry at the Alzheimer Disease Research Center of the University of Pittsburgh. He is a member of several organizations including the American Association for Geriatric Psychiatry, Biological Psychiatry, the Society for Neuroscience and the American Chemical Society. He has published numerous journal articles, book chapters and abstracts and is Principal Investigator of several NIH and Foundation grants. Dr. Klunk is a pioneer in the field of in vivo amyloid imaging in humans. His work spans from basic synthetic chemistry and neuropharmacological evaluation of amyloid imaging tracers to human PET studies of these tracers. His group’s preliminary report on amyloid imaging in humans was cited in Discover Magazine’s “100 Top Science Stories of 2002” and a recent paper describing this work was awarding “Best Neuroimaging Paper from 2002-2004” by the Alzheimer’s Association.
Chester A. Mathis, PhD, Scientific Advisory Board Member
Dr. Mathis is Professor of Radiology, Pharmaceutical Sciences, and Pharmacology at the University of Pittsburgh School of Medicine in Pittsburgh, Pennsylvania. In addition, he is Senior Chemist and Director of the University of Pittsburgh Positron Emission Tomography (PET) Facility. Dr. Mathis has a long standing interest in applying synthetic radiochemistry techniques to develop PET radiopharmaceuticals to study brain function in vivo. Over the past 20 years, Dr. Mathis focused primarily on the development of radiotracers to image the serotonin and dopamine neuroreceptor systems, as well as agents to evaluate other aspects of normal and abnormal function in the central nervous system using PET imaging techniques. Approximately 10 years ago, Dr. Mathis joined efforts with Dr. William E. Klunk at the University of Pittsburgh to devise a PET radiotracer capable of imaging amyloid. This work has been highly successful and has led to the development of a new class of imaging agents to non-invasively assess amyloid load in the living human brain.